Paper published in a journal (Scientific congresses and symposiums)
Antifracture efficacy and safety of once-yearly Zoledronic acid 5mg in men with osteoporosis: a prospective, randomized, controlled trial
Boonen, Steven; Su, Guoqin; Incera, Elodie et al.
2011In Osteoporosis International, 22 (Suppl.1), p. 112
Peer Reviewed verified by ORBi
 

Files


Full Text
OC35.pdf
Publisher postprint (40.68 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Disciplines :
Public health, health care sciences & services
General & internal medicine
Author, co-author :
Boonen, Steven
Su, Guoqin
Incera, Elodie
Orwoll, Eric
Kaufman, Jean-Marc
Reginster, Jean-Yves  ;  Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Rizzoli, René
Lippuner, Kurt
Vanderschueren, Dirk
Bucci-Rechtweg, Christina
Antunez, Oscar
Papanastasiou, Phil
Language :
English
Title :
Antifracture efficacy and safety of once-yearly Zoledronic acid 5mg in men with osteoporosis: a prospective, randomized, controlled trial
Publication date :
March 2011
Event name :
European Congress on Osteoporosis and Osteoarthritis ECCEO11-IOF
Event organizer :
International Osteoporosis Foundation and National Osteoporosis Foundation 2011
Event place :
Valencia, Spain
Event date :
du 23 mars 2011 au 26 mars 2011
Audience :
International
Journal title :
Osteoporosis International
ISSN :
0937-941X
eISSN :
1433-2965
Publisher :
Springer Science & Business Media B.V., Godalming, United Kingdom
Volume :
22
Issue :
Suppl.1
Pages :
S112
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 07 April 2011

Statistics


Number of views
123 (2 by ULiège)
Number of downloads
3 (0 by ULiège)

Bibliography


Similar publications



Contact ORBi